Furthermore, AGB-1 treatment resulted in an equivalent or marginally greater elimination of the mCherry HCT-116 Bd-WRN cells when compared with HRO761 (Fig. 6D, E), an allosteric WRN inhibitor with a growth inhibitory 50% (GI50) of 40 nM, currently in phase I clinical trials for MSI colorectal cancers58. The gene discussed is WRN; the disease is medical procedure.